<SEC-DOCUMENT>0001193125-15-018423.txt : 20150123
<SEC-HEADER>0001193125-15-018423.hdr.sgml : 20150123
<ACCEPTANCE-DATETIME>20150123110134
ACCESSION NUMBER:		0001193125-15-018423
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150122
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150123
DATE AS OF CHANGE:		20150123

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEOGENOMICS INC
		CENTRAL INDEX KEY:			0001077183
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-TESTING LABORATORIES [8734]
		IRS NUMBER:				742897368
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35756
		FILM NUMBER:		15544252

	BUSINESS ADDRESS:	
		STREET 1:		12701 COMMONWEALTH DRIVE
		STREET 2:		SUITE 9
		CITY:			FORT MYERS
		STATE:			FL
		ZIP:			33913
		BUSINESS PHONE:		9419231949

	MAIL ADDRESS:	
		STREET 1:		12701 COMMONWEALTH DRIVE
		STREET 2:		SUITE 9
		CITY:			FORT MYERS
		STATE:			FL
		ZIP:			33913

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERICAN COMMUNICATIONS ENTERPRISES INC
		DATE OF NAME CHANGE:	19990120
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d858122d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section 13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): <U>January&nbsp;22, 2015</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>NEOGENOMICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Nevada</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-35756</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>74-2897368</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>12701 Commonwealth Drive, Suite 9, Fort Myers,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Florida</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>33913</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(239) 768-0600 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;22, 2015, NeoGenomics,
Inc. (the &#147;<U>Company</U>&#148;) issued a press release regarding its raising of its revenue and earnings-per-share guidance for the fourth quarter of 2014 (the &#147;<U>Press Release</U>&#148;). A complete copy of the Press Release is attached
hereto as <U>Exhibit 99.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in <U>Item&nbsp;2.02</U> of this Current Report on Form 8-K, including <U>Exhibit 99.1</U>
furnished pursuant to <U>Item&nbsp;9.01</U>, is being furnished and shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;), or otherwise subject
to the liabilities of that Section. The information in this <U>Item&nbsp;2.02</U> of this Current Report on Form 8-K, , including <U>Exhibit 99.1</U> furnished pursuant to <U>Item&nbsp;9.01</U>, shall not be incorporated by reference into the
filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act of 1934. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Not applicable </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Not applicable </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Not applicable </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"><U>Exhibits</U>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Press Release of NeoGenomics, Inc. dated January&nbsp;22, 2015.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"><B>NEOGENOMICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Douglas VanOort</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Douglas VanOort</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: January&nbsp;23, 2015 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit Index </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of NeoGenomics, Inc. dated January 22, 2015</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d858122dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g858122ex99_1logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEOGENOMICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRESS RELEASE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>FOR IMMEDIATE RELEASE
</U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NeoGenomics Raises Revenue Guidance to $25 Million and EPS Guidance to $0.01 - $0.02 per share for Quarter 4, 2014 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Company Now Projecting 36% Year-Over-Year Revenue Growth in Quarter 4 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Ft. Myers, Florida &#150; January&nbsp;22, 2015 &#150; </B>NeoGenomics, Inc. (NASDAQ: NEO<B>), </B>a leading provider of cancer-focused
genetic testing services, announced today that it was raising its previously issued revenue and earnings-per-share guidance for the fourth quarter of 2014. The Company now expects revenue of approximately $25 million and earnings per share of
approximately $0.01 - $0.02 for the fourth quarter. Previously, the Company had issued revenue guidance of $23.0 - $24.5 million and earnings-per-share guidance of $0.00 - $0.01 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Douglas VanOort, the Company&#146;s Chairman and CEO, commented, &#147;On a consolidated basis, including the results of our newly acquired
PathLogic business, we are expecting approximately 36% year-over-year revenue growth in the fourth quarter. Approximately 23% of this growth is coming from our core NeoGenomics business and the remainder from PathLogic. The improvement in earnings
guidance reflects continued strength in our underlying business. We look forward to sharing our final audited fourth quarter financial results and to reviewing key growth initiatives as part of our Quarter 4 Earnings Release and Conference Call,
both of which are scheduled for February&nbsp;24, 2015&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reserves the right to adjust this guidance at any time based on
the ongoing execution of its business plan. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company&#146;s securities, and are reminded that the foregoing estimates should not
be construed as a guarantee of future performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About NeoGenomics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NeoGenomics, Inc. is a high-complexity CLIA&#150;certified clinical laboratory that specializes in cancer genetics diagnostic testing, the
fastest growing segment of the laboratory industry. The company&#146;s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing.
Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States. For
additional information about NeoGenomics, visit <U>http://www.neogenomics.com</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interested parties can also access investor relations material from Hawk Associates at
<U>http://www.hawkassociates.com</U> or <U>neogenomics@hawk.com</U> and from Zack&#146;s Investment Research at <U>http://www.zacks.com</U> or <U>scr@zacks.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for
historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future
results to differ materially from those anticipated in the forward looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the
company&#146;s ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company&#146;s periodic filings with the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information, please contact: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>NeoGenomics, Inc.</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><B>Hawk Associates, Inc.</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Steven C. Jones</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Ms. Julie Marshall</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Director of Investor Relations</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">(305)-451-1888</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(239) 325-2001</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">(212) 825-3210</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>sjones@neogenomics.com</U></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><U>neogenomics@hawkassociates.com</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g858122ex99_1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g858122ex99_1logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`BP!'`P$1``(1`0,1`?_$`,0```(!!0$!`0``````
M``````@)``(#!@<*`04$`0`"`@,!`0``````````````!@4'`@,$`0@0```&
M`0,#`00$"`L)``````$"`P0%!@<`$0@A$A,),4$B%%&!%3AA<7(6=K87&)&A
MP3)B)+4V-[=X\$*B(S-#=5:F$0`!`@0$`@0'"PL!"0`````!`@,`$00%(3$2
M!D%182(3!W&!,D*R,Q3PD:&Q4F)R<Q4U-L&"PB-#L\,D='46X='QDE-D)55E
M)O_:``P#`0`"$0,1`#\`[^-$$31!$T01-$$31!$T01:.L0F_=OL4=A$`W]V_
MNZ[:\*@,X('ZA9^J^1\TYSPW6P-(N\#-<=HW&9:KHK,4+1D%C.S85$WC)LE,
M0<''M'+DO<(D!^0H@4Q1U*5EFJZ"V4EX?&EJM[3LP<REM24ZY?)4HF1XR/*(
MJDN]-6W*JM;$E.4FC609C4L*5H\(`Q'2((;W?[;ZC.B)6)H@B:((FB")H@B@
MQ^T=NT1Z;]-O9OM[Q#6.J2I'*#P9Q94<D3(<XE,($#N,`;?"7WF'<=@`H=1_
M!KS6,N/*##C@!GT0AOU%/61J.'E'7'GA\9OG+E;:GQ:E%A4VY;76,=STB<&2
M":PQXK-[?>4U3_U6+:BJB@KL=XH0I!2/=O=]W0UE\EN/=P-OVDP-:RX=#CB$
MXG2%>2V<BLXGS09@Q5&\>\JEML[+MO\`F[\[-(*!J0VHX`3'E+Y`8#&9PE!M
M>FCQ/L/%#CC'PV19-Q8\[Y5GI+,.?+/(.C2$A*9+N)47$@Q=20B8SXM99D29
M>0!$BBR:AR?"<`TF=X6YZ?=&XE/VU`;L%,V*>D;`D$L-DZ3+FO%>..,CE#3L
MJP.6&R)16$JN[ZBZ^HXE3BL9$_-!T\L,(8GI(ANB:((FB"*3&[0#Z1'8`^G7
MA(2)G*"!QR/R0K%1=*5RKM%K[=A!4I8*!4\[5@*9!,HM,221%$FJ38OQ*E)W
M&3*`B?L`.X-B&W%2PP/BGX)\>0XQBI83AB2,^@<SPETSPA+/)?UL:)Q_46C8
MNYPV9LOQU@>J3..<<)-Y''T1%K,FZ+:OS&2">2$))13U!0[@(]>0<D,ML(B8
M#$"X]H]R.[-SI15U39H+:X,%O`ZR)YH:S,QD52'BBLMQ]Z>W[&I5-2DUE>@^
M2WY`.6+GDX<1.<+'=\J?5!]7.U%QA0YF'X[8-GU19RJT(_E*!0?LU0_:LA8<
MAO!-<<B/3E((!&QQRI+G#M%`@#N%NJVWW2]SC(K[LHW/<*#U$JT..:AR:'ZM
ML<=2\1P,5K]L=X/>4\JBH1[+:#,**)MM2G(ZG)ZED?)!D?DG..A3T_?26X\<
M%F#6UQI#Y-SJ[8&1E,NV>.;IN(H'28E?QN/X'=9I3XAP)Q*=0AE9!R3HLN)1
M[`HC?W>GN+?BO97R*6PI/5IFR=)`.!<5@7#R!DD<$Q;6T.[RR[3E5)'M%W.;
MRQE/,(3D@8YCK$<980U@I>TI2^T2E`N^P!OL&WL#8`U6?0(?XJT01-$$:UR-
MEBE8OC3/[3,-VZYR[LHEN(.9B1-[`*T8$."@E$>GD.)$B^\VO4I4LR0)F/"9
M#IA4G+SGM"8UI[VQY:M9\0T=9`5(6AU[LE<RY$*L4WRK1A$@NU58-)`>GS+D
M[)B4NYN]<"B&G3:6R+_NVM0Q96M20>NZK!EO@2I4I$IX!,R3AA.%O<FY+5MV
MC747)?5PTH3BI9ED!S)Z0`,8YD<D<QN2G/.V*8/PR:MX!Q#+J*I/X5[D*+I+
M&5B2*%3-*9JS#/+Q"DPB'>4QXQF"3$#G[4F:QOC'ZLLO=]L?NJH?MJ]E5??9
M`A?9ZU$G+L&$SD3P4K$2\H8B/G&\[RW)OJL-NHC[+:22-':!M('$N.DB8'+$
M3(D)XP4W&CT\>/F+FCB7Y%'XU<@+&+9T@@Q9<_\`&N/<=P'E*=--\RBF-.<3
MLO)-P[3IJ/7?@*H7;Y8WM%5W1WK[FO-1V.UTUE!0S3G1.N/*D,E$DID>20.1
M,35@V59:#];?#25M0`0`*MM#8!.8!!*CAYQ..($;PQ]R;?XNDI3'D.KC/)F!
MJL5<*U2)7-E+LD]58I`5%WY<=9!B(:H'8HLQZHHBS5:/!Z_*B([C`WO9M!N"
MA1<KPE=%N1R04XEI2$J4?)+K:BJ<^)S3P,H<[1N46U9IF>Q5:TX);[5"I2^2
M4RD.B4C#;>-/,U"RQS8N*;:.2(ALV3<OL2755.-RQ6V8E*H8T'V*+I6J,22$
M1(M'&=IB0-SH(;ZI;<.S+QMQ1]O:_E=75>1-32OSO-5QDJ0X3BR[7?+?<4@,
M.`+EY"O*\0R/B)AF.-<W4/*"0)P<F#.;2(/SM8EB@QG&:Q.BQ/ECF$KM-(P"
M'>B)PZ?%VCTTHK0I/@X'\L3*5!67^O\`OC;P"`^P0Z:QC*-`9RR(^K#=C5J_
M9HNHVFQ,9!]&S$Y%/I&.*SBR]\BD@LQ(Y^3E`0$3HF5;JIF[1`-C;:V--J<4
M$H&I1,@.9.48+<2V"I9`2`2284'29+-G**P._P!V6%D$H99XHA8N6N8V:H-R
MK)'$CTN,*D\*[!5VGW#X5U0<NTAVW*R'V6>;)M_:30J=WN!ZY%`*:)E6.(F.
MV7P&4P)`_.RA5%PN%W<[*T)**5*I%Y8D9S\U.1Y0JGE'PB87KU`Y?!<_<+'<
MJ%A?&]$N68[39<P8UQMD')-KR2A)2@N*W+98F&,"S3,1%!J(IB^69-D1$>\Z
MH"%U[8WY4VON]^VJ5IABOK*EQNG;0RZMEI#6F?:!A"U$G$B>DJ,I8`B*=W38
M?M3>2K4ZM9M]*RA3A+K;:UEP3ZA=4E`E@,"9"<'Q"2E?XOXI8U^G3V5*/C>I
MD3;QE=IW*/T[)10[AP<H""+)M2WTK-2[U0!.LNN919383J'V#<*X-/6[JO"J
MA]-._<WE$J6MBZ`>'-(2D<`)`0PTZ*>R6\,4_:(H$8!*7[>J1/&<BHJ/G$F-
M-LW.:N2BK6<O&1;J7#991RYAZPKR7X.5VTODFHE1;J.Q>0D&@N`B!MG2K82D
M-W>%,0^/3"M=EVDDL6UI"[_(!3BF;@ML3S"<5^\#X8T+37750=J'%BB)P';T
M"9RR,I)^+I$%/3$)>EQ+6L4BSY6BHQ`YA1CHSEMZ<"JBJY^IUEU%*>N[>NE-
MNJBICG'Z=)5>\BI=77W!-.5D=92F+H$B?`8@)`X1,4J'I]C3*=4>0?MQ498#
MF3[\!'F>T1.:,A1-?H[+D!<.0C*R1M=J=@?WK!5@BW2G<43#%S&$:#7GTT[C
ME2=B;@[U-NS(!U04$A=AYZ;>QV^W[';4T-1;G1-Q$JC3+B)/J,B>)"3TQ-TM
M@JJYPOUJZMI]!D@*4P?')I(]*#UOT7R3XR1L?,<F*RKEO'S!M&**\B,4+D1R
M107!RMTQ0O#)0&2-K;1[U0$BO7/B66``$KWN$$]:&K?M3>BI;=<^SKZ<J5V:
MF7#B3V*P.KADF6`\T#&)13]WLDOM%/M%"3ZQ'EHZ5@Y_'TF&,8^S`]>X]R#!
MR>096??06(9'("-["N'C58.#D*R$K$+E3!R,M-2[5@^2='$4TSD4+X@,<P=V
MJW71OBN31@#MB]V<OG!>DX^]#,EY!8[0'JA!,_%.+/*X-\A8M#W&@+\`_AVA
ME1#?\0Z]H?7H^L1Z0@J?4K^@KT3&.^EX0O[D^(1[=Q!2Z;;;[@`W.;`0#;J&
MFKO,$]Z5F&/ZO]VC_;$3M@G[&;\*_2(_(!"K_6)H&4.->?<>^HQB:+0G*:ZK
M,7A/DG'*4ZEW9S%UI&;3=5RTH1=Z@;)76:KMNJ+%%^NU,1F\0;%./C<&U9O=
M!7VO<5DJ>[F[N%NM4X:BB4EUQH%S3I6A2FU)41D=(.()EB(J_O,H*^SW1G>E
MN1J9T!JH!;0Y),Q)82L%(F)C409$##&-%X`K=NYL$5Y%(UW)5PQE`.W$;6@H
M^,>`$46)6B'@O'+.]U^=FZPUC#HH=JC@KAD3YH=C;@B!=Y[<E92;%3_BX=IV
M;BM.IXN/W(SF,.S4E*L\9249>&..RM*W,W]K4@?=I`=(*6*`*21FE:9ISP\T
M1F>0N5U4K)+#"UV7N[JZQ!R,6J%BX[\`E:>H\,4P'.>RX^K-Y2?(L#=I3IMP
MW.;<H'+L(ZJRNOM#1E.A+54F4R&:NY3$_E!Q3<OAASI++45:"EU2V%`R&NDH
M9F0\T)2N8]Z/I8TXD\MN<Y*Q,Y#CZECS'$;XU6UM>XNIF/4Y,1[O)*U^F5"O
MU]Y8)!<@B!'*_B:%`-BJ^X5.KOE8XI:0]4)87^S[9U:0.`ZZS.73#71V:B8;
M2.R8+R1(K#3:%$CC)"0`?!ARAY_&3A+A'BXR!Q388\[=W+,6DMD6R`D[LKQ-
M4I0<-8_L(5G7XQ80'=!H0@G+L"IU-@'4`MPKX`#E$RE`3CQE&.>HJF0.%/(C
M8H?!36I2_@+^<$+T#35W=R.]K>.3Y]%41M_'_9WOH?E$#5C,`+2<X%#H`\-(
M@!`/Z6)87?\`AWUSN8;J3+_ROQO"-;9(LRE#/V2?CTG&"*Y6_P"(6+/_``%_
M_L574-0^O3]8CTA$E4^I7]!7HF/A>ES]RC$/Y=U_7.;TV=Y/XTK/S/W:(A]L
M?<S?TE^FJ/R>IU<Z?5.+EDBK-(1Y%;C,PL/'UAP5)9Q=4T'R#N5A4F*A#D<L
MTF*?E<G4#PD(0`..YB%-$;3N;5EOC-R<2H]D%D:?*"M)EI.`!GD2<([KM2BO
MH5TBP%(7(%)D0H3Q!F#A\/*.7?%^!K5)0><)[BWC5PE#`U1E;CBNF9(24F+"
MG&$2=,ZU#UNR69":MRK3RG>(LR-U/&4YBI`(^-,SO=]Q[C[PJVC8W2_V5NGH
M14+:(0@:L%*6A,\,`5>3/.0F82*&T;>V8Q55%A:+M;,J6T%S4K`S2A"U##BF
M?6D"!RADOH^Y'X$98D6=>LL$\A.8D,X63=T7-9F7RAW+%PJ55;$K!P@TB7SE
M@!-EV[M'[<:J%,($`@=^M6_^[#<FSD)KTGVS;SDBFH:!T"?G.IQ*-0P2KR#A
M(SC/:'>!:-RN&D4/9;PG`M+(ZPF9=FK)7SDX*!F,L8Z<4>T"`'3X1$H=?8!?
MAV#?80VVVU50,Q.4HL61B]KV"`A]1;[E/(K]#FOZP0NF[N[_`!M0?7GT51%7
M_P"YWOH?E$#7C8`"F9MV]_"^'$?QCB."'?7.[^*D_P!P_C1J1]S*_I/T#!"\
MJB]^2<6E$>@UO(`_66%<&_C$`U#T'KT_6(](1)5)_5+^K5\1CX7I<?<GQ`/T
M'N@__9S8?RZ:^\H?_:UGA1^[1$3MG[F;^DOTU0$?-['Y,X<PWD5;9>FRU,Q=
MC^LP\9B^:SS6\(72PRES92<TO.T9S98::8R1&;H4"NC&*@"JB*20J]I3%U%6
M*E:>07W@ZEA*YZPPIY$QP6E)3,$=.?"-=[K%L$4[);4^M,M/;I86!\I!4%3,
M\)$2E`8WO`66\"RKZYPV!\F67%;]DU5FFN6\$<=.5C.O),SE[GD?;L,RC2VI
MMT$!$4GJ0LU$TS=BO0`,%VVR]V6_4*;9653%-<T@I;[!^IHPJ?DA;:T]D,L4
MDD8Q65;:[A2N*JE,5#C2CUB[3T]5("6(<;4%D_.D#`PYJXJ<?N3+*'MF#LR\
M/<!9OCY-*P&F7\AG3C!:'K\5DCE0LU-R*[N\*QGVCM(/DY&*E&ADSAN"BA#;
M%:;%N[<>TG56W<%'=;E85HT%`33U383CBVIH)F#Q0L'``D`PL7C;5JO"$OVV
MIM]'<4F>HE^F6HSPFEV:00?.21+&1Q@GN'/K'Y.XU7AMQ:]2<GSAX@[:,K/(
MV%?1EJ2&).;Y2*E+C*UA:0B[Y4'I"E%*R1AE7!"`(O$U#@HH5=W;W/6K<]O.
M[^[`DM+F7*-0*2%9J2V%2*%I_P"4OJ_(/")S;7>96V.H_P`>WOBIL`"H!"N@
M%13Y2#\M,R>(,XZDZM9:_;Z["V>KS</8J]/QR$M"S<%(-9.(EHUX4%FS^.?L
MU56SMHNF<!*<AA*.^OFEQEVE<52U*5-U+:BE25"2DJ&8(.((Y1>S+[-4TFII
MEI<IU@%*DD$*!R((P(@0O46^Y3R*_0YK^L$+IL[NOQM0?7GT%1'7_P"YWOH?
ME$#9C?\`N9FW_1=#?Y106M#OXJ3_`'#^-&IO[E5_2?H&"&Y4?XE8M_1K(7]B
M.=0]!Z]/UB/2$2-3ZI?U:OB,8_Z70;\)L0!_3NF_XOSSF]]-7>5AO6L/(H_=
MHB*VS]S-_27Z:HT+ZCF/+5CBRPO+RDXXH>4XR&JYL?YCH.1ZFQM]8DZT#Q5U
M6+0]8KMUW;0D+(O#(K.VPD6;D,F)MTO*&EFU53E,\E*7JAE&O42THI4,/-Q`
MU>'#QQV7&C:JVE%;-.ZK3(=JG4/'@3+P<8&/'URP-<XZ/FHO"?%6'FIF/3>F
MB,"<R+#QHR4Q55,=)9HXH%CCL9,D7":Q#E["RCALIL!@4$A@$;!:K*JM0JJI
M:ZX.4Z1(JJ*)-6`.EP%TH!X=4'#HA"J*2EH7.PJ:.B:?.08JU4TY\DGLP3XS
M&+9!P-+5)!+(.#:WSTQ/96WS#MS$2\)1.6.+;0U4'RN&8R-9?Y@=*MG(;]Z;
MLAF*Y1V-XQV,#-;-QL5;8M>X%VFKHE`)"@IREJ$<C-24(3+H,TQ&U%`XRDU%
M"+PPYGBENJ:XS$P5J4/#GS@<9.M8"Y8U*RXHS):^%V,\LMTE&9%,H\;YCBID
MR)DCF$[&6@+]7;+!-2/FBIR"Y8/H)5-<!V%(Z1MRL*';_L^X,W:Q)NU399B?
M8U0K6E#(H6@@R!X*2K#F#$#5TUFOM.Y1UKUM:K=0ZSM,JC="I32H+3)*Y<0I
M,CRE`M8/Y'\J/1/S#"8UR+/0>>N)-V<B]04Q]9V]PHL@R64($Q9,2S@JB-5N
MD.<_>^@G)4$7Q=C"0/(DZ!QO&WMJ]]UJ=NEH:7;]Y4XDH/)T.3E@EY($E(5D
MAP8HRX$0N6F^7WNRN+=!6K15[>=49=DH+2H'SFC.:2/.093/1C'3%S&R72<P
M>G/E?)^.YYI9J3>L5P5FK4XR$?!(14E,P:J*O8/QMW"1NY-9$^RB"Q#)G`#%
M$-?-NS+?5VGO%I;7<$%JN8JE(6@\%!*ICI'$'(C$1]!7"NI;EMI5PHE!=(\R
M%)/,$B6'`\P<C&J,;_W,S;_HNAO\HH+48[^*D_W#^-&YO[F5_2?H&"(Y3@(Y
M+Q:`?^LY#'ZBP3D1_B#4/0>N3]8CTA$E4^J7]6KXC&/^EQ]R?$'Y=T_7.:TU
M=Y7XUK/S/W:(B=L?<S?TE^FJ#_?L64FS=1TBT;/V#YNNT>L7B*;EH\:N4CHN
M&KINL4Z+ANND<2'(<!*8HB`AMI&R,QF(G3B)<(0[RD].RXX:G97./$B*BY^#
M,DZ<6W"%@KL+>69&1A,NY"OURSL9.,M=?2W$_P!EKI'>-C``M3'``(21HZ]]
M@H2A;C>DSFA:D'I'5(Q//A'%54--4I(=:;<FDB2TA6/`XSRY2QXP&F),R8VE
MF*2UQB^+>-;ZG(FCEXR*I7(;B]+/WIS*@5U$WOC78K)"M5D@2$JQ7L"P%%7?
MNW)JPZ&[*N[QIT*N"W$HP"UT]6GIZM6$<L`%$Q7M?:!:4>T."A`*L"A%13JE
MP!-,5#QZ=,LXS_(M7'*[%.Q8LLN2K/E&&^36A%L<<Q\#\JXI1-@J*B<:]J^=
MQIV62`!0V;`+5=0@AXQ3,4PZ:[)<?L<^S71NG19GYAPNTE32D:L-06R5,X<=
M(QS!EG"U!]KDNC>J'*E(P#=4Q5)$L<6W@EXSZ?!&%H-,-\@L63==SA`<9(*Q
M"=Y`6T^6N$>1,"6:NRRQET65@C,\X95<4Z`F#'*90BZS/8JZ9R"D9/<![J@W
MG:MW;>L#M?\`9^D.(+5>W4(<1AU#3/Z"I///AC..-35MO%"MNYMT27YE)+M&
MMA:?GI>9"D@\03+IB[PU<RT#Z3?/K"Z]PA<A5K!&9KK1:1=*S)N)FKS5>>/Z
M/85%:S+.&S([V$-+2+A5(X(HE,9<Y@(4#;:W;M[.J[W+)>D,KIZFNI&7G6UB
M2TKTK3UP">M)(PF9#".S8JWD;-N%N4ZEYFFJ5H0L$E)3U3U"<TSQ'AAG..2"
M%+S8/N_<L@]PZ[[GQ%";!_PZI1TC_+$#_P!A_&$6@C"QG^C_`$#!"\HQ']I^
M,`WZ!5,B#]8P3T/Y-0E#Z]/UB/2$253ZI?U:OB,8_P"EQ]R?$'Y=T_7.:TV=
MY7XUK/S/W:(B=L_<S?TE^FJ&%:1HGH\$H#L(@`B'\T1#V#](#[0T00L;F3Z=
M=/SPN[R5BUVTQEG%J'VB668@I'U^Y/VX@H@-B*P!-:+G!53#Q2S8/,!^JQ50
M`!+L0]HFE7D$2XCX1\4:UMA?AY?Z>X<X3I-YKS'0+A+XZYEL(^=E:PT:-X2-
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M_1NR5B.P*-E\@RE07O\`E)RV5!PB:^V^Q5YU(QJ#L`W=-:ZQ0;QQ5=S`L9L9
M0!$#AJ@G-W#>O?%37EO"@2\&V!E)EM*PG#YV*I'+5+A%VV?;B]M[&-"]I%<I
M/:.RQ':+*20"<2$B0Z9$QOC'._YE9N_T60`_7^R&&U7SOXL0?^O_`(PAK1]R
MG^D_0,$YR3KLM)7VCS:"":4+!U.Z$EIE^Z:1L2P6E&"\=&MW$B^6;MB.7KQP
M0B:8&$YM]]M@$0@J1:6W4J5.06DF6.`(),N,A$H^"IM21F4D>,@@?#`A^GSR
M2H&'<>U+B=FLDIA_+]3=S2;-E?D$XBO6]"=G'TNS<U>S>16'>%,1X!"=ZI".
M!`!0.J`[!9.^[#<+Q7.[NLFBMLKR4DJ9.I31"4I(<1Y2?)Y0M6&XTU"R+3<"
M6*U"E8+$@K4HGJG(YPX0C@AR$.`@`'*!@^(!Z"&Y1Z>XP#T'WZJH$GA[O=PA
MLCWS==A`-Q#<H%'N$W3?8``-^FA2PD3^#C'H!]V4*UYA>KMP[XCEEH"?N?[3
M,JL4E$DL48K<-;%/)/=C@FVL\X10E8J"7EV!4';D71`W[6YQ#;5D;1[J-Y[S
M*7Z&G]GMI(_7O30@<RE)ZRS+()!PQG"'N+O&VUMTJ8<=]HN"1ZIJ2C/@%*P2
MF9PQ.<<J_*;G+R_]4BPLHN+Q\THN&:U+*,D`J=4GIF%IK=^0QG3W*.7X^O2<
MN#4C(AE'+9`K9H8"")6AS]HC].;<[N=B=V"/;+BX*W<B4$I[0I#AYAADJPU9
M))$^D8Q1-\WKN[>Y["G0JGM,^L&PHH2#@0ZX`=4L9RPPRXG:/!J)IO"#.4%F
MV.CV&?BUPSZ!D;2C3;;!0<*RDTDH^3=T=S9H..2AK"DDL(,G3G_FN$E.P2(@
MJ8I:O[Y]S;MO5&+<\VBCV^Z$D-I<275+!F$NZ5$SZ`"F?G&46%W;;=VY:ZGV
MI+GM-Y2)A10H-IPD>S*D@3&(Q(/(<8Z$N8W,S$&;\$S^`\%FG\P9.S74XHD-
M`4J)7>?FNT<.8V5,YN;Q8$6D.X:I-C$7;]QCMS@/E%,@=^J[V+MFYVVYL;JN
MX11V2F7JUO'25]4C2A/E*./*+)OESIGZ9=MI)O5BQ+2C$C$9].$;9QW1;(6C
MY;620C7;:5XJM*2W>L9V&>1Z-KAL=QT!)0C]^W?':Q[MK(M%`,98Q$13+Y`.
M*?Q:3G*MG_(16S_EQ6A4_F%S5/WHDVZ=?V66?VG8:)=.DCXX8/?,>5/),*>"
MMT8629=XK-S`JHW=,7/8)"NF3E(040<%*/MZE$.@@(=-08*ABDD'HB2("A(Y
M0NS-O$%\-<6@WM>:9OQ>B=1="MSA#(7.J=W51W59IEXI.,=$`-^]@<I%-@\S
M50NX:FK1?+A9:KVRV.*9?/E:927T+2KJJ'0??C@JZ!JK:##R0X!D3Y0GR5F(
M!*8Y677T[ZF2XGR@EE;CNSEFT(KAK+4DC&YOJCIX?L3AZ#+F3[K:BU*0?A3*
M*3<@=R[5N3=4+0M%GM7>G7*H&Z4T6ZM&LOL))IE2\YT?LYG`$>4<B<H3;K=G
M-E4HK*AT.VPJT]FLCM)G@@^<#PE@GCF(4SR2]5OF7ZAMP5Q'@9=3CMAJ:=KQ
MJC.'F'<?+R$6F0XNG63<H1K)5XS9_*F[U8Z*312$OP&*Y'J-V;<[I]F]W=$F
M][FG<;PVD*`T30%8R2TV2`5924O+/"*9OW>!N7=SZK?;-5%:R983!D>+C@X<
MP,#R(QC`<7\&^.>$EG]MY0Y$PUR`23`5HW'E#Y&6[%'V@98@][B2*_PN>V3+
MH''>`G2>L6I3!NH8W4-=%V[P=RWW10[2IJRW\W5TK3I$CD"*@(2D"6.@JY".
M*V[1M%M4:F^/TM8`)H:14.-:L,9E3)4>/G2/&"H7S##EIT?1L,0V1L/X"8O8
MVO*XOQSS1F[+8;#]H+M7*Z$?5%X)`KM?PJ>0O>BF@KW!Y55CF`HK*+,^U5KK
M[N:2MW`0IP/NT2$-(D,UN`F>/22#D!.'2D>0*=+%K0^Q:DJ2DMLUBE2GR$DS
M_P"'WX,>`Q!EFU12E,M-TS+AGCS8&[1&*X[3%X6R?EN\HG?)R2+Z792$<@TJ
M+J6>)IJG4=$(8FP`DS5``-JNKONK;UM>-2EFBN>Y4JU&H#*6J=M0&`$L5Z<A
MSEB>$/ENL-P=40X[54]K5YBW5+*QQ/,$]/B`@D.`W'D\Q)<AL;*RSJLTO'F4
MTHN2:,&\<%QGDY&)2?(5NP6EHU15=HP*:`)*I'[B)N#*=J*9A':K;]?KG?:A
M-7='5.K`ZHGU$=*4@R$.5OMU'0M%JF0$HYYJ/YWE?##F8?%E&K]2DZ1"P3:-
MKTS'/8N5;M1.FZD6TBR58/#/)#N%ZX<JMEC!Y3'$Y=_A$-+IF3,DY2B3D)2E
MA&PM$$65R@9/8=_:`].H]/HUBKR<<H]!D9F.9/,/"B4]4?U-<_ADBP/*WQGX
M@HTS&2497/`UF;C?IRJL+A*QJ*P@4C/S.)7R2S\>YR9FDV:HF)W"HG]#V7>;
M/==W:TGV*VA>Y[TIQY2U?LVFUJ:02..*?U:3A/4H@R$4C<MM/[\WQ4IN*RFQ
M6TH;"1YRE)2M21](GKG,@`"4X+/(G"&N8UA:_'HTD:3%T%LW:4#-?'MJ6IW.
MD-VAMV9;'$1YFJ5E9H'$1.+P?F1W'9[UVU6M#OZ^I><<K'?;J=]1+K%2=:%D
MYE.K%M7+3)(Y19)VQ:T,I:HVFZ4-3T+:ZJD_2EY7CZ8"27XO<I+#D0MXL_)E
MU9ZF@_9NV>=[%D.0F8YNU:"99O5T<5/VSF<&T$3^,(PR'RY?^I\QV#Y=68QW
MA[&I[,:>CH`U4$$*I4-@$J.:B],=3A,$'A+"%9W:U\7<!4.53RF@9]HI9TRY
M:`.7"4H,['6#:'B.*?96<R[>C-%CG<6/E%GETV=9"L"ZP&%U^SV%6.J6#,Z^
M($DX\JKPP`!?FC;`7577W=]TOJ!1+TLVU(TIIV9I0!F-1S6<<R90X6^RT=N5
MV[8"J@F96H#/C(<OA@=[KR^?6F?+A;@M2;+)7"X+K13O,DVV%UDZR&<@*<@O
M4VRXF1H\*<#&.K(N!(NFC\9@1,'=I6#,AUY!L8R$2@4$3#0D3G*'/\+N-A.,
M.%HVE2#TDQ=IZ0<W#(<ZFJ==.0MDNF@#I!LX5_K#EE%H(D;IJJ?$L)#*B`"H
M(!S.N=HO5PX>"-R$Z4],%KK7&<31!%M0O<7;ION';N(@'=[NH:Q6)B4&/#.`
M<Q31'>&>7G(U0&1BTSE`C2LNP$N0.YHSR;1ZVWQ]D>J.U0#9%Y)5Z,AYAF4V
MPKD%YV[^`VF:XW!N[;<H&UF5=;@ME0/G-+676U2^:M3B21\R%JWT+EMW#6J2
M":.NT.A7!+J4A"TD]*0A0G\Z"KOF0J!C&LOK;D:T050K+-,P.I6P/$6;4YC@
M81;(D5'ROW2P%V*@B1153V%*.EI*.T/53.<,A('E&$)Y[]1/'LC8%:OQ2PLP
MG)EY.C(LKA9Z\\>M7EA%K]FDE:EBUJ(E>N_`<0(J^3`HB('^5[OBUWML*TR=
M5U2)2Z.DQI4OY`QC&Z)P#YB\NK$TOW)FYSE)@U3E426NROVC;P8J"!C-:M0V
MZB$756_B'8@+@T*0/^R?;;7O;-,IT-C*/-#BS-64.ZX\<4<,<9()2*QK64DI
M5\@FC/7*8,62MU@$GQ"#Z643(9NS%3XBM&Q46I!Z@3NZZXW'%.'K91N2A*!A
M!)`&P;![`Z!K",HFB")H@B:(("'FGS"JW%*I1(HP:-RRE<G"S6@4I/<1<KI;
M-U9R7^6(H_1B6J[@J12HE^8>+G!%+;XSDVLM%Q1D98>X1K<6$@<<?<87K1N"
M'(_F)/,LO<U,ASU6AG(D=P&.(P$4)UC&K'!0C)K$*`M!X_9*)&V[12=21PZK
M=A^NMY?0UU6@(P#:EXK,-KPOQ@P9Q^8D:8MQ[!0#OQ%3=6)9N,I:Y'X>TYGU
MDD3.)10%-QW3*H1'KT(&N9;BUGK&-J4)3D,8WYL'MV#?\6L(RCW1!$T01-$$
M31!'@CL'\`?BW';?ZM>$R@@`<*8#-?\`/.1N6N8HPSZSFM$W2L&UR52!1I0L
M>TN3>UZ/L:#)<HE3L=H=M7#Q-42[MTE^],>Y;<NY2M*0V,LSX8Q`F=1@_P#6
MJ,HFB")H@B:((FB")H@B:((I/_--[/9[_9]>B"*$_=^3]7M_W?=MH@B[H@B:
..((FB")H@B:((FB"/_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
